Description: Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 " NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.
Home Page: www.medesispharma.com
L'Orée des Mas
Montpellier,
34670
France
Phone:
33 4 67 03 03 96
Officers
| Name | Title |
|---|---|
| Dr. Jean-Claude Maurel | CEO, Pres & Member of Management Board |
| Ms. Tessa Olivato | Member of the Exec. Board and Director of Admin. & Financial |
| Ms. Solene Guilliot | Member of the Exec. Board and Director of Medical Affairs & Clinical Devel. |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 74.9148 |
| Price-to-Sales TTM: | 189.3087 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |